Recently there has been increased evidence that patients with Crohn’s disease (CD) commonly have disrupted sleep, and disrupted sleep correlates with the risk of disease flare. The sleep/wake cycle, immune function, and multiple biological processes are orchestrated by the circadian clock. The central circadian clock in the brain entrains these processes to the environment by light exposure, and CD subjects have evidence of misaligned circadian rhythms that correlate with subclinical inflammation. The long-term goal of this research proposal is to show that bright light therapy in CD improves barrier integrity, reduces markers of subclinical inflammation, and modifies the microbial structure/function to an anti-inflammatory state. To test this hypothesis, we will conduct a randomized crossover trial of morning bright light therapy (60 min) given by a wearable device (Re-timer™). We will do three assessments in inactive CD subjects at: 1) baseline; 2) after four weeks of wearable glasses with bright light therapy; and 3) after four weeks of wearable glasses without bright light therapy. The results of this innovative proposal will improve quality of life in CD subjects, reduce the risk of disease flare, and identify novel circadian regulated targets for the treatment of CD.